Adhikari Nilanjan, Amin Sk Abdul, Jha Tarun
Natural Science Laboratory, Department of Pharmaceutical Technology, Division of Medicinal & Pharmaceutical Chemistry, PO Box 17020, Jadavpur University, Kolkata 700032, India.
Pharm Pat Anal. 2018 Nov;7(6):259-276. doi: 10.4155/ppa-2018-0019. Epub 2019 Jan 11.
Histone deacetylase 8 (HDAC8) is one of the attractive therapeutic anticancer targets. HDAC8 has been overexpressed in a variety of human cancers. Therefore, HDAC8 inhibitors offer beneficial effects in the treatment of solid and hematological tumors. Different HDAC inhibitors entered into different phases of clinical studies. However, selectivity towards specific HDAC8 enzyme is still demanding. In this patent review, a number of patented selective and nonselective HDAC8 inhibitors along with their implication as anticancer agents have been discussed in details. Molecules should possess modified fish-like structural arrangement to impart potency and selectivity towards HDAC8. This comprehensive patent analysis will surely provide newer aspects of designing selective HDAC8 inhibitors targeted to anticancer therapy in future.
组蛋白去乙酰化酶8（HDAC8）是一个颇具吸引力的抗癌治疗靶点。HDAC8在多种人类癌症中均有过表达。因此，HDAC8抑制剂在实体瘤和血液肿瘤的治疗中具有有益作用。不同的HDAC抑制剂已进入不同阶段的临床研究。然而，对特定HDAC8酶的选择性仍有待提高。在本专利综述中，已详细讨论了许多已获专利的选择性和非选择性HDAC8抑制剂及其作为抗癌剂的意义。分子应具有改良的鱼状结构排列，以赋予对HDAC8的效力和选择性。这一全面的专利分析必将为未来设计针对抗癌治疗的选择性HDAC8抑制剂提供新的思路。
